Related Experiment Videos
Conservative management of pediatric pancreatic pseudocyst using octreotide acetate
C Mulligan1, C Howell, R Hatley
1Department of General Surgery, Eisenhower Army Medical Center, Fort Gordon, GA 30905.
Insights
Octreotide acetate effectively treated pancreatic pseudocysts in two children when used alongside conservative care. This approach offers a safe, potential alternative to surgery for pediatric pancreatic pseudocyst management.
Area of Science:
- Pediatric Gastroenterology
- Endocrinology
- Surgical Research
Background:
- Pancreatic pseudocysts in children are rare, often resulting from trauma.
- Current treatments range from conservative management to surgical drainage.
- Octreotide acetate, a somatostatin analog, has shown efficacy in adult pseudocyst management and post-surgical settings.
Observation:
- Two pediatric patients with pancreatic pseudocysts were treated conservatively.
- Treatment included bowel rest, hyperalimentation, and octreotide acetate (2.5 mcg/kg SQ QD).
Findings:
- Complete resolution of pancreatic pseudocysts was observed in both children within 5 weeks.
- Octreotide acetate demonstrated safety and efficacy as an adjunctive therapy.
Implications:
- Octreotide acetate may be a valuable, safe, and effective addition to conservative treatment for pediatric pancreatic pseudocysts.
- Consideration of octreotide acetate before surgical intervention is warranted.
- Further research into octreotide's role in pediatric pancreatic pseudocyst management is suggested.
Abstract:
Pancreatic pseudocysts in children are rare. A total of 213 cases have been reported in the literature, the majority secondary to trauma (65%). Treatment options range from conservative, non-operative management to operative drainage. Octreotide acetate, a long-acting analog of somatostatin, is a synthetic peptide with a variety of endocrine and gastrointestinal functions. Octreotide has been successfully used following pancreatic surgery to reduce exocrine function and most recently in the management of adult pancreatic pseudocysts. We report the efficacy of octreotide, as an adjunct to treatment, in two children with pancreatic pseudocyst. Each child was treated conservatively with bowel rest, hyperalimentation, and octreotide acetate (2.5 micrograms/kg SQ QD). Complete resolution of the pseudocysts occurred within 5 weeks. We conclude that octreotide acetate is a safe and potentially effective adjunct in the treatment of pediatric pancreatic pseudocyst, and should be added to the management of pseudocyst before drainage procedures.